The 340B Drug Pricing Program has been under scrutiny in recent years. In 2022 there have been some significant developments. Here is a recap of some of the key 340B Program headlines from this year so far. 340B Is Key in the Fight to End Viral...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of our service...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of our service...
SCL 340B Care is happy to share insights, news, and comments relevant to the 340B program to help you stay informed. Learn about current legislation, technology solutions, administrative challenges, and more that impact the program, safety net providers, drug manufacturers, and the health of Americans. Senate...
SCL 340B CARE offers the tools necessary to ensure patients have appropriate access to medications and dispensing activity is accurately monitored and accounted for. Our end-to-end solution offers: Contract Pharmacy AdministrationPharmacy Contract NegotiationDirect EMR/HL7 ConnectivityThird-Party Capture, Billing, Collection & RemittanceVirtual Inventory Management & Reconciliation ...
Recently, there has been an increase in legislative efforts for the 340B program. Lawmakers have introduced policies at the state level with the hope that they would prove successful and be adopted nationwide. Some of these efforts could greatly improve the benefits of safety net...
One year ago, The Medicare Negotiation and Competitive Licensing Act was introduced to increase transparency and allow the government to negotiate drug pricing with manufacturers. Recently, the Senate Finance Committee introduced the Prescription Drug Pricing Reduction Act of 2019 to address the high costs of...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of...
Congress has been closely investigating the problem of skyrocketing prescription drug costs and pricing practices. As a result, pharmaceutical drug manufacturers are ramping up their lobbying efforts this year. Pharmaceutical Research and Manufacturers of America (PhRMA) represents 37 of the countries’ biopharmaceutical research companies and has...
The 340B Drug Discount Program has faced numerous attempts at regulatory changes in the last five years; one, in particular, challenged the Orphan Drug rule. The ruling stipulated that manufacturers are not required to provide covered entities orphan drugs under 340B, but a manufacturer may, at...